Clinical Trial Update: Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of ALX148 in combination with liposomal doxorubicin and pembrolizumab for recurrent platinum-resistant ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ALX148
• Doxil (liposomal doxorubicin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Alexander B Olawaiye, MD | Conditions: Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING